Two medications have been added to the Saskatchewan Drug Plan Formulary, both benefitting those with ALS, or Lou Gehrig’s Disease.

Albrioza and Radicava have now been listed on the formulary, as the Government of Saskatchewan expands treatment options for those living with ALS.
Minister of Health Everett Hindley says, “Providing patients living with ALS additional treatment options is crucial, given the speed at which this disease progresses.” The Saskatchewan Drug Plan Formulary is a publicly funded plan, therefore the costs of the medications under it are covered.

ALS is a neurodegenerative disease that affects around 3,000 Canadians, and eventually leads to fatality. The disease quickly takes patient’s ability to move and talk, and daily activities, such as feeding or cleaning themselves, are affected. A news release from the province says there is currently no cure for ALS, but medications such as Albrioza and Radicava may help slow the rate of disease progression.